搜尋結果
16 小時前 · lovastatin pitavastatin pravastatin rosuvastatin simvastatin These may differ by how much the body absorbs, which enzymes process the statin, how the statins interact with cells, and how the body ...
4 天前 · Overall, statins reduce TG levels in the range of 10% to 20% ( Table ), although it has been acknowledged that the higher the baseline TG level, the greater the TG-lowering effect. For example, baseline TG levels exceeding 250 mg/dL have been associated with reductions in the range of 22% to 45%, whereas more modest reductions have been ...
3 天前 · There are differences among the statins in terms of their propensity to cause myopathy. The statins that carry a higher than average overall risk are among the more potent: lovastatin (Mevacor, Merck; Altocor, Andrx; and generic) and simvastatin (Zocor, Merck).
其他人也問了
How effective is Lovastatin vs niacin?
Does fluvastatin XL uptitrate a statin?
Is pravastatin safe?
Is rosuvastatin safe?
5 天前 · Directly compare the efficacy of one drug to the other. Underpowered for a head-to-head comparison of mg-equivalent doses of the 2 most potent statins, ARIES does show benefits for LDL-C reduction in an unfortunately ignored population, African Americans.
1 天前 · It has the advantage of a long half-life compared to other statins (e.g., lovastatin, fluvastatin, and simvastatin), with the half-life of atorvastatin reported to be approximately 7 h. However, the half-life of its HMG-CoA reductase inhibitory activity is approximately 13–16 h, owing to the action of its active metabolite [ 32 , 33 , 34 ].
1 天前 · Background: the purpose of this systematic review was to assess the clinical and radiographic effect of subgingival-administered statins as an adjunct periodontal treatment in patients with periodontitis. Methods: Electronic literature searches in Medline/PubMed and the Cochrane Library were conducted to identify all relevant articles. Eligibility was based on inclusion criteria which included ...
5 天前 · Some studies, such as one showing an association between lovastatin use and reduced melanoma incidence (OR, 0.52; 95% CI: 0.27–0.99, p = 0.04), suggest potential benefits [7]. In vitro research has demonstrated that statins can inhibit melanoma metastasis and augment treatment in BRAF inhibitor-resistant melanomas when used with other drugs [ 3 ].
